Full-Time

Quality Assurance Associate 2

Capricor Therapeutics

Capricor Therapeutics

201-500 employees

Biotech developing cell- and exosome therapeutics

Compensation Overview

$70.3k - $82k/yr

San Diego, CA, USA

In Person

On-site in San Diego, California; occasional time in GMP cleanroom environments.

Category
QA & Testing
Required Skills
ISO 9001
RDBMS
Word/Pages/Docs
Google Cloud Platform
Excel/Numbers/Sheets

Get referred to Capricor Therapeutics

Find people who can refer or advise you

Requirements
  • Bachelor’s degree in a relevant field (e.g., Biology, Biotechnology, or related discipline) or equivalent experience.
  • 0-3 years of experience in a regulated environment (e.g., cGMP, GLP, GCP).
  • Familiarity with regulatory standards such as 21 CFR 210 and 211, ICH, ISO9001, and FDA guidelines preferred.
  • Strong attention to detail and excellent organizational skills for managing documentation and records.
  • Proficiency in Microsoft Office Suite (Word, Excel, PowerPoint) and familiarity with database systems.
  • Strong written and verbal communication skills for effective collaboration and reporting.
  • Ability to work independently and as part of a team in a dynamic, fast-paced environment.
  • Comfortable gowning and working in classified areas as required.
Responsibilities
  • Assist in batch record review and disposition for clinical product manufacturing, including label issuance, product packaging, and shipping activities.
  • Support the issuance, tracking, and archiving of controlled documentation in compliance with GxP (GLP/GCP/GMP) regulations.
  • Maintain and manage controlled records, including batch/test records, logs, reports, and quality management documentation.
  • Assist in preparing materials for internal audits and ensuring documentation readiness for regulatory inspections.
  • Help process and track training records to ensure company-wide GxP compliance.
  • Participate in the review and release of incoming materials in accordance with company standards.
  • Support controlled label issuance, including inventory tracking and updating lot numbers.
  • Collaborate with senior team members to improve and implement quality management systems and training programs.
  • Assist in preparing reports and documentation related to deviations, corrective actions, and change controls.
  • Support the maintenance and management of documentation systems, both manual and electronic, ensuring timely and accurate record-keeping.
  • Perform additional quality assurance tasks as assigned.
Capricor Therapeutics

Capricor Therapeutics

View

Capricor Therapeutics develops cell- and exosome-based therapies to treat serious diseases. Its products use cells or tiny vesicles released by cells to repair heart tissue, Duchenne muscular dystrophy, and COVID-19–related complications, and are advanced through research and clinical trials before potential commercialization. It differentiates itself by focusing on cell- and exosome-based approaches rather than small molecules, pursuing a portfolio aimed at high-need conditions. The company’s goal is to improve patient outcomes by validating these therapies and bringing them to hospitals and healthcare providers, supported by partnerships and grants.

Company Size

201-500

Company Stage

IPO

Headquarters

Beverly Hills, California

Founded

2005

Get referred to Capricor Therapeutics

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • HOPE-3 met primary PUL 2.0 and key cardiac endpoints, strengthening approval odds.[3][5]
  • Capricor targets an August 22, 2026 PDUFA decision for deramiocel.[3][5]
  • The company is expanding manufacturing capacity and commercial infrastructure before launch.[3]

What critics are saying

  • FDA review remains binary after the earlier CRL and resubmission process.[5]
  • The NS Pharma dispute threatens U.S. commercialization even if approval arrives.[3]
  • Capricor remains highly dependent on deramiocel, with preclinical exosome programs unproven.[1][3]

What makes Capricor Therapeutics unique

  • Deramiocel is an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy.[3]
  • Capricor combines cell therapy and proprietary exosome platforms in rare diseases.[1][3]
  • Its U.S. commercialization agreement with Nippon Shinyaku adds an external launch channel.[3]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Staff Training (not in predefined)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $23 Million Registered Direct Offering

SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Provides Corporate Update and Reports First Quarter 2016 Financial Results

HOPE-Duchenne and ALLSTAR Clinical Trials on Track to Complete Enrollment in the Third Quarter Company to Host Conference Call and Webcast at 4:30…...

Capricor Therapeutics, Inc.
Mar 25th, 2026
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

Institutional Investors Include: Broadfin Capital, LLC and Sabby Capital, LLC LOS ANGELES, Feb. 4, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics,…...